Thats why we built BriefLink, a new software tool that minimizes the upfront time of getting the VC meeting
Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH (2018) Inhibition of Interleukin-1 by Canakinumab and cardiovascular outcomes in patients with chronic kidney disease
A new Gallup poll shows 11% of adults say they are currently using one, a dramatic increase from just two years ago, when 3% said they were using them
This decision was made to protect members and customers access to quality care at affordable rates
In contrast, semaglutide produces 15-22% body weight reduction in rigorous randomized trials, making it the evidence-based standard of care for weight management